1. Johnson CM, Wilson DM, O’Fallon WM, et al. Renal stone epidemiology: A 25-year study in Rochester, Minnesota. Kidney Int 16:624-631, 1979.

2. Sutherland JW, Parks JH, Coe FL. Recurrence after a single renal stone in a community practice. Miner Electrolyte Metab 11:267-269, 1985.

3. Coe FL, Keck J, Norton ER. The natural history of calcium urolithiasis. JAMA 238:1519-1523, 1977.

4. Parks JH, Goldfisher E, Asplin JR, Coe FL. A single 24-hour urine collection is inadequate for the medical evaluation of nephrolithiasis. J Urol 167:1607-1612, 2002.

5. Consensus Conference. Prevention and treatment of kidney stones. JAMA 260:977-981, 1988.

6. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones. New Engl J Med 327:1141-1152, 1992.

7. Evan AP, Lingeman JE, Coe FL, et al. Randall’s plaque of patients with nephrolithiasis begins in the basement membranes of thin loops of Henle. J Clin Invest 111:607-616, 2003.

8. Bushinsky DA. Nephrolithiasis: site of the initial solid phase. J Clin Invest 111:602-605, 2003.

9. Klugman V, Pak CYC, Favus MJ. Nephrolithiasis in primary hyperparathyroidism. In The parathyroids: Basic and clinical concepts. Bilezikian JP, Marcus R, Levine MA, eds. Academic Press, San Diego, 2nd edition, p437-450, 2001.

10. Parks JH, Coe FL. A urinary calcium-citrate index for the evaluation of nephrolithiasis. Kidney Int 30:85-90, 1986.

11. Lemann J Jr. Pathogenesis of idiopathic hypercalciuria and nephrolithiasis. In Disorders of bone and mineral metabolism, Coe FL, Favus MJ, eds., Lippincott Williams Wilkins, Philadelphia, 2nd edition, 2002.

12. Coe FL, Parks JH, Moore ES. Familial idiopathic hypercalciuria. N Engl J Med 300:337-340, 1979.

13. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. Family history and risk of kidney stones. J Am Soc Nephrol 8:1568-1573, 1997.

14. Favus MJ. Hypercalciuria: Lessons from studies of genetic hypercalciuric rats. J Am Soc Nephrol 51:S54-S58, 1994.

15. Scott P, Ouimet D, Valiquette L, Guay G, et al. suggestive evidence for a susceptibility gene near the vitamin D receptor locus in idiopathic calcium stone formation. J Am Soc Nephrol 10:1007-1013, 1999.

16. Reed BY, Gitomer WL, Heller HJ, Pak CYC. Mapping a gene defect in absorptive hypercalciuria to chromosome 1q23-q24. J Clin Endocrinol Metab 84:3907-3913,1999.

17. Reed BY, Gitomer WL, Heller HJ, Hsu MC, Lemke M, et al. Identification and characterization of a gene with base substitutions associated with absorptive hypercalciuria phenotype and low spinal bone density. J Clin Endocrinol Metab 87:1476-1485, 2002.

18. Weber S, Hoffmann K, Jeck N, Saar K, Boeswald M, et al. Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis maps to chromosome 3q27 and is associated with mutations in the PCLN-1 gene. Eur J Hum Genet 8:414-422, 2000.

19. Vezzoli G, Tanini A, Ferrucci L, Soldati L, Bianchin C, et al. Influence of calcium-sensing receptor gene on urinary calcium excretion in stone-forming patients. J Am Soc Nephrol 13:2517-2523, 2002.

20. Vezzoli G, Soldati L, Proverbio MC, Adamo D, et al. Polymorphism of vitamin D receptor gene start codon in patients with calcium kidney stones. J Nephrol 15:158-164, 2002.

21. Rendina D, Mossetti G, Viceconti R, Sorrentino M, Castaldo R, Manno G, Guadagno V, Strazzullo P, Nunziata V. Association between vitamin D receptor gene polymorphisms and fasting idiopathic hypercalciuria in recurrent stone-forming patients. Urology 64:833-838, 2004.

22. Asplin JR, Favus MJ, Coe FL. Nephrolithiasis. In The kidney, Brenner BM, ed., W.B. Saunders, Philadelphia, 6th edition, p1774-1819, 2000.

23. Insogna KL, Broadus AE, Dreyer BE, Ellison AF, Gertner JM. Elevated production rate of 1,25-dihydroxyvitamin D in patient with absorptive hypercalciuria. J Clin Endocrinol Metab 61:490-495, 1985.

24. Li X, Tembe V, Horwitz GM, Bushinsky DA, Favus MJ. Increased intestinal vitamin D receptor in genetic hypercalciuric rats. J Clin Invest 91:661-667, 1993.

25. Karnauskas, A.J., Favus, M.J., Asplin, J.A., Shah, M.L., Parks, J.H., Coe, F.L. Elevated vitamin D receptor level in human idiopathic hypercalciuria. Annual meeting of the American Society for Bone and Mineral Research, Toronto, September 24, 2000.

26.Peacock M, Nordin BEC. Tubular reabsorption of calcium in normal and hypercalciuric subjects. J Clin Pathol 21:353-358, 1968.

27. Coe FL, Favus MJ, Crockett T, Strauss AL, Parks JH, Porat A, Gantt CL, Sherwood LM. Effects of low calcium diet on urine calcium excretion, parathyroid function and serum 1,25(OH)2D3 levels in patients with idiopathic hypercalciuria and in normal subjects. Am J Med 75:25-32, 1982.

28. Melton LJ III, Crowson CS, Khosla S, Wilson DM, O’Fallon WM. Fracture risk among patients with urolithiasis: A population-based cohort study. Kidney Internat 53:459-464, 1998.

29. Weissinger JR, Alonzo E, Bellorin-Font E, Blasini AM, Rodriguez MA, Paz-Martinez V, Martinis R. Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria. Kidney Internat 49:244-250, 1996.

30. Gahzali A Fuentes V, Desaint C, Bataille P, Westeel A, Brazier M, Prin L, Fournier A. Low bone mineral density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria. J Clin Endocrinol Metab 82:32-28, 1997.

31. Coe FL, Parks JH. New insights into the pathophysiology and treatment of nephrolithiasis: new research venues. J Bone Miner Res 12:522-533, 1997.

32. Parks JH, Coward M, Coe FL. Correspondence between stone composition and urine supersaturation in nephrolithiasis. Kidney Int 51:894-900, 1997.

33. Coe FL, Wise H, parks JH, Asplin JR. Proportional reduction of urine supersaturation during nephrolithiasis treatment. J Urol 166:1247-1251, 2001.

34.Costanzo LS, Windhager EE. Calcium and sodium transport by the distal convoluted tubule of the rat. Am J Physiol 235:F492-F506, 1978.

35.Lemann J Jr, Pleuss JA, Worcester EM, Hornick L, Schrab D, Hoffman RG. Urinary oxalate excretion increases with body size and decreases with increasing dietary calcium intake among healthy adults. Kidney Internat 50341, 1996.

36. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 328:833-838, 1993.

37. Laerum E, Larsen S. Thiazide prophylaxis of urolithiasis: A double-blind study in general practice. Acta Med Scand 215:383-389, 1984.

38. Ettinger B, Citron JT, Livermore B, Dolman LI. Chlorthalidone reduces calcium oxalate calculous recurrence but magnesium hydroxide does not. J Urol 139:679-684, 1988.

39. Borghi L, Schianchi T, Meschi T, Guerra A, Allegri F, Maggiore U, Novarini A. Comparison of two diets for the prevention of recurrent stones in idiopathic hypercalciuria. N Engl J Med 346:77-84, 2002.

40. Broghi L, Meschi T, Amato F, Briganti A, Novarini A, Giannini A. Urinary volume, water and recurrences in idiopathic calcium nephrolithiasis: A 5-year randomized prospective study. J Urol 155:839-843, 1996.

41. Caruna RJ, Buckalew VM Jr. The syndrome of distal (type 1) renal tubular acidosis: Clinical and laboratory findings in 58 cases. Medicine 67:84-99, 1988.

42. Coe, FL, Parks JH. New insights into the pathophysiology and treatment of nephrolithiasis: new research venues. J Bone Miner Res. 12:522-33, 1997.

43. Pak CYC, Fuller C. idiopathic hypocitraturic calcium-oxalate nephrolithiasis successfully treated with potassium citrate. Ann Int Med 104:33-37, 1986.

44. Ettinger B, Pak CYC, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol 158:2069-2073, 1997.

45. Chadwick VS, Madha K, Dowlling RH. Mechanism for hyperoxaluria in patients with ileal dysfunction. N Engl J Med 289:172-176, 1973.

46. Dobbins JW, Binder HJ. Importance of colon in enteric hyperoxaluria. N Engl J Med 296:298-301, 1977.

47. Scheinman JI. Primary hyperoxaluria: Therapeutic strategies for the 90’s. Kidney Internat 40:389-399, 1991.

48. Klugman V, Favus MJ. Diagnosis and treatment of calcium kidney stones. In Advances in Endocrinology and Metabolism, Mazzaferri EL, Barr RS, Kreisberg RA, eds. Mosby, St. Louis, p117-142, 1995.

49. Coe FL, Kavalach AG. Hypercalciuria and hyperuricosuria in patients with calcium nephrolithiasis. N Engl J Med 291:1344-1350, 1974.

50. Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 315:1386-1389, 1986.

51. Yu TF, Gutman AB. Uric acid nephrolithiasis in gout: Predisposing factors. Ann Int Med 67:1133-1148, 1967.

52. Hall AP, Berry PE, Dawber TR, McNamara PM. Epidemiology of gout and hyperuricemia: A long-term population study. Am J Med 42:27-37, 1967.

53. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the national Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney Dis 40:37-042, 2002.

54. Silverman DE, Stamey TA. Management of infection stones: The Stanford experience. Medicine 62:44-51, 1983.

55. Williams JJ, Rodman JS, Peterson CM. A randomized, double-blind trial of acetohydroxamic acid in struvite nephrolithiasis. N Engl J Med 311:760-764, 1984.

56. Crawhall JC, Purkiss P, Watts RWE, Young EP. The excretion of amino acids by cystinuric patients and their relatives. Ann Human Genet33:149-169, 1969.